Mobile website
Archive > Volume 30 Issue 4 > 2023,30(4):286-295. DOI:10.3872/j.issn.1007-385X.2023.04.002 Prev Next
Expert Forum
Problems and countermeasures in the research of oncolytic virus anti-glioma treatment
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Glioma are the most common primary tumors in the brain, accounting for 81% of central nervous system malignancies. The current standard of care for patients with glioma is still surgical resection and postoperative radiochemotherapy. However, the prognosis of glioma is very poor with a median survival of only 15 months due to its highly aggressive nature, molecular heterogeneity,reproducibility of resistant cancer stem after therapy, and difficulty in crossing the blood-brain barrier (BBB) for chemotherapeutic agents to reach sufficiently high therapeutic levels. In recent years, the emerging oncolytic viruses (OVs) immunotherapy in the treatment of glioma has received much attention and made some progress. Nevertheless, multiple challenges still exist, such as crossing BBB, immune "cold" microenvironment, host antiviral response, and high tumor heterogeneity. These problems limit the further development and applications of oncolytic virus therapy but also bring new research opportunities to basic and clinical researchers.Therefore, this review summarizes the problems and countermeasures in the research and application of oncolytic virus in anti-glioma therapy from four aspects including crossing the BBB, improving the tumor microenvironment, adjusting the host immune responses mediated by oncolytic viruses, and adapting to tumor heterogeneity.
Keywords:
Project Supported:
Clc Number:
